Global Marketing Director - Pulmonary Hypertension and Rare Disease Team

 ...efforts for our first-in-class activin signaling inhibitor approved for the treatment of Pulmonary Arterial Hypertension (PAH) in many markets across the globe, which is in the middle of our global launch and has the potential to transform the PAH landscape. Earlier this...